Variable | Primary Tumor Radiotherapy | Standardized difference | P value | |||
---|---|---|---|---|---|---|
No (91) | Yes (91) | |||||
Number | % | Number | % | |||
Age | Â | Â | Â | Â | 0.0224 | 1.0000 |
  < 60 years | 43 | 47.3 | 44 | 48.4 |  |  |
  ≥ 60 years | 48 | 52.7 | 47 | 51.6 |  |  |
KPS | Â | Â | Â | Â | Â | 0.1700 |
 70 | 14 | 15.4 | 32 | 35.2 | 0.4674 |  |
 80 | 65 | 71.4 | 42 | 46.2 | 0.5313 |  |
 90 | 12 | 13.2 | 14 | 15.4 | 0.0628 |  |
 100 | 0 | 0.0 | 3 | 3.3 | 0.2611 |  |
T Stage | Â | Â | Â | Â | Â | 0.1156 |
 T2 | 10 | 11.0 | 5 | 5.5 | 0.2008 |  |
 T3 | 43 | 47.3 | 56 | 61.5 | 0.2898 |  |
 T4 | 38 | 41.8 | 30 | 33 | 0.1825 |  |
N Stage | Â | Â | Â | Â | Â | 0.1250 |
 N0 | 10 | 11.0 | 15 | 16.5 | 0.1601 |  |
 N1 | 44 | 48.4 | 29 | 31.9 | 0.3412 |  |
 N2 | 25 | 27.5 | 38 | 41.8 | 0.3037 |  |
 N+ | 9 | 9.9 | 7 | 7.7 | 0.0777 |  |
 Nx | 3 | 3.3 | 2 | 2.2 | 0.0673 |  |
M Stage | Â | Â | Â | Â | Â | 0.9395 |
 M1a | 50 | 54.9 | 50 | 54.9 | 0.0000 |  |
 M1b | 37 | 40.7 | 36 | 39.6 | 0.0224 |  |
 M1c | 4 | 4.4 | 5 | 5.5 | 0.0507 |  |
Differentiation | Â | Â | Â | Â | Â | 0.3212 |
 Well | 7 | 7.7 | 6 | 6.6 | 0.0427 |  |
 Moderate | 53 | 58.2 | 52 | 57.1 | 0.0222 |  |
 Poor | 28 | 30.8 | 33 | 36.3 | 0.1166 |  |
 Unknown | 3 | 3.3 | 0 | 0 | 0.2611 |  |
Chemotherapy Cycles | Â | Â | Â | Â | Â | 0.0940 |
 4 | 20 | 22.0 | 25 | 27.5 | 0.1276 |  |
 5 | 5 | 3.3 | 0 | 0 | 0.2611 |  |
 6 | 22 | 24.2 | 19 | 20.9 | 0.0790 |  |
 8 | 20 | 22.0 | 14 | 15.4 | 0.1698 |  |
 10 | 5 | 5.5 | 20 | 22 | 0.4932 |  |
 12 | 19 | 20.9 | 13 | 14.3 | 0.1739 |  |
Second-line Chemotherapy | Â | Â | Â | Â | 0.0000 | 1.0000 |
 No | 74 | 81.3 | 74 | 81.3 |  |  |
 Yes | 17 | 18.7 | 17 | 18.7 |  |  |
Chemotherapy Response | Â | Â | Â | Â | 0.1562 | 0.3680 |
 Poor | 42 | 46.2 | 35 | 38.5 |  |  |
 Good | 49 | 53.8 | 56 | 61.5 |  |  |
Metastatic Tumor Radiotherapy | Â | Â | Â | Â | 0.0880 | 0.6565 |
 Yes | 44 | 48.4 | 48 | 52.7 |  |  |
 No | 47 | 51.6 | 43 | 47.3 |  |  |